Minimally invasive technologies are finding their way into the suites of ophthalmology surgeons. Just over the past six months, Allergan PLC has acquired two pre-commercial medtech companies developing miniature implants to treat glaucoma and dry eye disease. Meanwhile, Glaukos Corp., a leader in the micro-invasive glaucoma surgery (MIGS) market, remains one of the more successful medtech IPOs of late, raising more than $100 million in June and sporting a market capitalization of close to $1 billion built upon a successful commercial launch. [See Deal]
Medtech in ophthalmology is maturing. Surgical systems in the past centered around correcting vision with the implantation of artificial lenses, clearing out cataracts or using highly invasive procedures to reduce...